Company: LNAI
Filing Date: 2025-11-28
Form Type: SCHEDULE 13D/A
Source: 0001214659-25-017353
Chunk: 0

Company: Lunai Bioworks Inc.
Filing Date: 2025-11-28
Form: SCHEDULE 13D/A
Chunk 0
---
") and (ii) 1,243,844 shares owned by Gumrukcu, of which Wittekind shares voting and dispositive power through a power of attorney dated June 24, 2022. Pursuant to an order of the United States District Court for the District of Vermont dated October 27, 2023, the 12,438,431 shares owned by Gumrukcu are subject to a writ of attachment to secure the plaintiffs' claim in The Estate of Gregory Davis et al. v. Serhat Daniel Gumrukcu (Civil Case No. 5:22-cv-123). (3) The percentage ownership disclosed in Row 13 is based upon the sum of (i) 23,432,391 shares outstanding as of November 10, 2025, as disclosed in the Issuer's Form 10-Q filed with the Commission on November 14, 2025 plus (ii) 3,133,333 shares sold by the Issuer according to the Form 8-K filed with the Commission on November 25, 2025.

| SCHEDULE 13D |

| Item 1.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Security and Issuer                                                                                                                                                           |
| (a)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Common Stock, par value $0.0001 per share                                                                                                                                     |
| (b)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Lunai Bioworks Inc.                                                                                                                                                           |
| (c)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 2080 Century Park East, Suite 906, Los Angeles,                                                                                                                               
 CALIFORNIA                                                                                                                                                                    
 , 90067.                                                                                                                                                                      |
| Item 1 Comment:This Amendment No. 23 amends the Schedule 13D filed by Weird Science LLC, a California limited liability company ("Weird Science") and William Anderson Wittekind, a member and manager of Weird Science ("Wittekind") with respect to the shares of common stock, par value $0.0001 per share ("Common Stock") of Lunai Bioworks Inc. (the "Issuer") received by Weird Science pursuant to that certain Agreement and Plan of Merger dated January 12, 2018 (the "Merger Agreement") by and among the Issuer (then known as DanDrit BioTech USA, Inc.), DanDrit Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Issuer ("Merger Sub"), Ren